https://orcid.org/0000-0002-6330-3784
About the Authors
- Takashi Shigematsu
-
Roles Conceptualization, Writing – review & editing
* E-mail: docteur_shigemat@iris.eonet.ne.jp
Affiliation Department of Nephrology, Wakayama Medical University, Wakayama, Japan
- Shinji Asada
-
Roles Data curation, Formal analysis, Investigation, Methodology, Writing – original draft
Affiliation Medical Affairs Department, Kyowa Kirin Co., Ltd., Tokyo, Japan
- Yuichi Endo
-
Roles Data curation, Formal analysis, Investigation, Methodology
Affiliation R&D Division, Kyowa Kirin Co., Ltd., Tokyo, Japan
- Takehisa Kawata
-
Roles Data curation, Formal analysis, Investigation, Methodology, Writing – original draft
Affiliation Medical Affairs Department, Kyowa Kirin Co., Ltd., Tokyo, Japan
- Masafumi Fukagawa
-
Roles Conceptualization, Writing – review & editing
Affiliation Division of Nephrology, Endocrinology, and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, Kanagawa, Japan
- Tadao Akizawa
-
Roles Conceptualization, Writing – review & editing
Affiliation Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan
Competing Interests
TS received consulting fees from Kyowa Kirin Co., Ltd. (KKC), Ono Pharmaceutical, Taisho Toyama Pharmaceutical, Fuji Pharma, and FUSO, and lecture fees from KKC, Chugai Pharmaceutical, Bayer, Kissei Pharmaceutical, Torii Pharmaceutical, Ono Pharmaceutical, and FUSO. SA, YE, and TK are employees of KKC. MF received consulting fees from KKC and Ono Pharmaceutical; lecture fees from KKC, Bayer, Torii Pharmaceutical, and Ono Pharmaceutical; and grants from KKC and Bayer. TA received consulting fees from KKC, Astellas Pharma, Bayer, Fuso Pharmaceutical, Japan Tobacco, Ono Pharmaceutical, Sanwa Chemical, Otsuka, GSK, and NIPRO, and lecture fees from KKC, Chugai Pharmaceutical, Bayer, Kissei Pharmaceutical, Torii Pharmaceutical, and Ono Pharmaceutical. This does not alter our adherence to PLOS ONE policies on sharing data and materials.